Composition for enhancing skin elasticity or improving skin wrinkles
A cortexolone-based composition activates autophagy in skin cells to enhance elasticity and reduce wrinkles by inhibiting MMP-1 enzyme expression, addressing the inadequacies of existing skin aging solutions.
Patent Information
- Application Number
- KR1020210074923
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-06-09
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-06-09
AI Technical Summary
Current solutions are inadequate for improving skin elasticity and reducing wrinkles due to external and internal factors that impair skin function, such as ultraviolet rays, fine dust, metabolites from gut microorganisms, and stress hormones, leading to accelerated skin aging.
A composition comprising cortexolone, its salt, stereoisomer, hydrate, or solvate is used to activate autophagy in skin cells, specifically fibroblasts, thereby inhibiting the expression of the MMP-1 enzyme and enhancing skin elasticity and reducing wrinkles.
The composition effectively improves skin elasticity and reduces wrinkles without side effects by activating autophagy and inhibiting MMP-1 enzyme expression, as demonstrated by experimental results.
Smart Images

Figure 112021066674691-PAT00002_ABST
Abstract
Description
Technology Field
[0001] This specification relates to a composition for improving skin elasticity or improving skin wrinkles. Background Technology
[0002] The skin is an organ located on the outermost layer of the human body that serves to protect the body from various external stimuli. Among the layers of the skin, the epidermis prevents the evaporation of moisture from within the body. The epidermis is divided into the stratum corneum, stratum granulosum, stratum spinosum, and stratum basale in order from the outside; the cells of the stratum corneum act like bricks, and the intercellular lipids between the keratinocytes act like mortar, forming the skin barrier.
[0003] It is known that normal skin function is impaired by external stimuli such as ultraviolet rays and fine dust, as well as internal causes such as metabolites produced by gut microorganisms and stress hormones, thereby accelerating phenomena such as loss of elasticity, keratinization, and wrinkle formation; however, there are currently almost no solutions to control this.
[0004] Autophagy is a process that removes unnecessary substances or waste products from within cells. Activating autophagy in fibroblasts eliminates these wastes, thereby inhibiting skin aging symptoms such as loss of elasticity, keratinization, and wrinkle formation. Therefore, there is a need to develop substances that enhance skin elasticity and improve wrinkles by activating autophagy. Prior art literature
[0005] Korean Published Patent Application No. 10-2019-0051350 The problem to be solved
[0006] In one aspect, the present invention aims to provide a composition for improving skin elasticity or improving skin wrinkles. means of solving the problem
[0007] In one aspect, the present invention provides a composition for improving skin elasticity or improving skin wrinkles, comprising cortexolone, its salt, stereoisomer, hydrate, or solvate as an active ingredient.
[0008] In one exemplary embodiment, the cortexolone, its salt, stereoisomer, hydrate, or solvate composition may be administered at a dosage of 1.7 to 17 mg / kg / day.
[0009] In an exemplary embodiment, the composition may activate intracellular autophagy.
[0010] In an exemplary embodiment, the composition may inhibit the expression of the MMP-1 enzyme.
[0011] In an exemplary embodiment, the composition may be a food composition or a cosmetic composition.
[0012] In one aspect, the present invention provides a composition for activating autophagy comprising cortexolone, a salt, stereoisomer, hydrate, or solvate thereof as an active ingredient.
[0013] In an exemplary embodiment, the autophagy may be autophagy in a skin cell.
[0014] In an exemplary embodiment, the autophagy may be autophagy in skin fibroblasts.
[0015] In an exemplary embodiment, the composition may be a food composition, a cosmetic composition, or a pharmaceutical composition. Effects of the invention
[0016] In one aspect, the composition according to one embodiment of the present invention has excellent effects of improving skin elasticity and improving skin wrinkles without side effects.
[0017] In one aspect, a composition according to one embodiment of the present invention can activate autophagy within a cell.
[0018] In one aspect, a composition according to one embodiment of the present invention can inhibit the expression of MMP-1 enzyme. Brief explanation of the drawing
[0019] Figure 1 is the result of measuring the cytotoxicity of cortexolone according to one embodiment of the present invention. Figure 2 is the result of measuring the expression of LC3II by cortexolone treatment according to one embodiment of the present invention. Figure 3 is the result of measuring the inhibition of MMP-1 enzyme expression by cortexolone according to one embodiment of the present invention. Specific details for implementing the invention
[0020] The present invention will be described in detail below.
[0021] In one aspect, the present invention provides a composition for improving skin elasticity or improving skin wrinkles, comprising cortexolone, its salt, stereoisomer, hydrate, or solvate as an active ingredient.
[0022] In another aspect, the present invention provides a composition for activating autophagy comprising cortexolone, its salt, stereoisomer, hydrate, or solvate as an active ingredient.
[0023] In one embodiment, the cortexolone can be represented by the following chemical formula 1.
[0024] [Chemical Formula 1]
[0025]
[0026] In this specification, "salt" refers to a salt according to one aspect of the present invention that is acceptable in medicines, cosmetics and foods and has desirable activity of a parent compound. The salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, phosphoric acid, etc.; or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvate, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2,2,2]-oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, (2) may include an acid addition salt formed from an organic acid such as tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, or muconic acid; or a salt formed when an acidic proton present in the parent compound is substituted. Additionally, the salt may be a pharmaceutically acceptable salt.
[0027] In this specification, “pharmaceuticalally acceptable” means that it is approved by a government or equivalent regulatory body, or listed in a pharmacopoeia, or recognized by other general pharmacopoeias, for use in animals, more specifically in humans, by avoiding significant toxic effects when used at a normal medicinal dosage.
[0028] In this specification, "stereoisomer" includes optical isomers, for example, essentially pure enantiomers, essentially pure diastereomers, or mixtures thereof.
[0029] In this specification, "essentially pure" means that, for example, when used in relation to enantiomers or diastereomers, a specific compound that can be exemplified as an enantiomer or diastereomer is present in an amount of about 90% or more, preferably about 95% or more, more preferably about 97% or more, or about 98% or more, even more preferably about 99% or more, and even more preferably about 99.5% or more (w / w).
[0030] In this specification, "hydrate" refers to a compound to which water is bound, and is a broad concept that includes inclusion compounds in which there is no chemical bonding force between the water and the compound.
[0031] In this specification, "solvent" refers to a higher-order compound formed between molecules or ions of a solute and molecules or ions of a solvent.
[0032] In this specification, "active ingredient" means an ingredient that exhibits the intended activity alone or can exhibit activity in combination with a carrier that is inactive itself.
[0033] In this specification, "autophagy" refers to a mechanism for regenerating energy and removing damaged substances by breaking down aging or damaged intracellular materials and organelles when intracellular energy sources are depleted or intracellular stress factors occur excessively. Cells can be maintained only when this autophagy occurs normally. If autophagy in the skin is inhibited, conditions such as skin pigmentation, dermatitis, acne, allergies, atopy, and psoriasis may occur.
[0034] In one embodiment, cortexolone, its salt, stereoisomer, hydrate, or solvate by administration of the composition may be administered at a dosage of 1.7 to 17 mg / kg / day. If the dosage of cortexolone, its salt, stereoisomer, hydrate, or solvate by administration of the composition is less than 1.7 mg / kg / day, it may be difficult to achieve skin elasticity enhancement and skin wrinkle improvement effects, and if it exceeds 17 mg / kg / day, it may irritate the skin. Specifically, the dosage of cortexolone, its salt, stereoisomer, hydrate, or solvate administered by the administration of the above composition may be 1.7 mg / kg / day or more, 2 mg / kg / day or more, 2.5 mg / kg / day or more, 3 mg / kg / day or more, 3.5 mg / kg / day or more, 4 mg / kg / day or more, 4.5 mg / kg / day or more, or 5 mg / kg / day or more, and 17 mg / kg / day or less, 16.5 mg / kg / day or less, 16 mg / kg / day or less, 15.5 mg / kg / day or less, 15 mg / kg / day or less, 14.5 mg / kg / day or less, 14 mg / kg / day or less, 13.5 mg / kg / day or less, 13 mg / kg / day or less, 12.5 mg / kg / day or less, or 12 mg / kg / day or less.
[0035] In one aspect, a composition according to one embodiment of the present invention can activate autophagy within a cell.
[0036] In one aspect, a composition according to one embodiment of the present invention can inhibit the expression of the MMP-1 (matrix metalloproteinase-1) enzyme.
[0037] In one embodiment, the autophagy may be autophagy in skin cells.
[0038] In one embodiment, the autophagy may be autophagy in skin fibroblasts.
[0039] In one embodiment, the composition may be a cosmetic composition. The cosmetic composition may have, for example, a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, an eye cream, an eye essence, an essence, a cleansing cream, a cleansing lotion, a cleansing foam, a cleansing water, a pack, a powder, a body lotion, a body cream, a body essence, a body cleanser, a hair dye, a shampoo, a rinse, a hair styling agent, a hair growth agent, an ointment, a gel, a cream, a patch, a spray, a powder, and a skin-adhesive type, but is not limited thereto.
[0040] In addition, for each formulation, other ingredients other than the essential ingredients mentioned above may be appropriately selected and combined by a person skilled in the art without difficulty, depending on the type or purpose of use of other external preparations.
[0041] The above cosmetic composition may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
[0042] In addition to the compounds of this specification, the cosmetic composition according to this specification may further include functional additives and ingredients included in general cosmetic compositions. The functional additives may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids, and seaweed extracts. The cosmetic composition according to this specification may include other ingredients that can provide a synergistic effect to the main effect, preferably within a range that does not impair the main effect. Furthermore, the cosmetic composition according to this specification may further include moisturizers, emollients, surfactants, UV absorbers, preservatives, disinfectants, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, cooling agents, or limiting agents. The amount of the above ingredients can be easily selected by a person skilled in the art within a range that does not impair the purpose and effect of this specification, and the amount may be 0.001 to 10 weight%, specifically 0.01 to 3 weight%, based on the total weight of the composition.
[0043] In one embodiment, the composition may be a food composition. The formulation of the food composition is not particularly limited, but may be formulated, for example, into tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. For each formulation of the food composition, in addition to the active ingredient, ingredients commonly used in the field can be appropriately selected and combined by a person skilled in the art according to the formulation or purpose of use without difficulty, and a synergistic effect may occur when applied simultaneously with other raw materials.
[0044] A food composition according to one embodiment may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and promoters (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Additionally, food compositions according to one embodiment may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not particularly important, they are generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one embodiment.
[0045] In one embodiment, the composition may be a pharmaceutical composition. The pharmaceutical composition may be a composition for the prevention or treatment of atopic dermatitis, psoriasis, eczema, or flushing. The pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intramuscularly, intraperitoneally, subcutaneously, etc. Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, liquids, emulsions, or pellets, but are not limited thereto. Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches, or sprays, but are not limited thereto. The above formulation can be easily prepared according to conventional methods in the field and may additionally include surfactants, excipients, wettable powders, emulsification promoters, suspending agents, salts or buffers for osmotic pressure control, coloring agents, spices, stabilizers, preservatives, preservatives, or other commonly used auxiliary agents.
[0046] The present invention will be described in more detail below through examples and the like. These examples are solely for the purpose of illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0047] [Experimental Example 1] Measurement of cytotoxicity
[0048] Human dermal fibroblasts (Normal human dermal fibroblast, LONZA) were placed in DMEM (Dulbecco's Modified Eagle's medium) containing 10% fetal bovine serum (FBS) and cultured at 37°C under 5% CO2 conditions. The cultured human dermal fibroblasts were treated with cortexolone (Sigma Aldrich) at various concentrations (5 μM, 10 μM, 25 μM, 50 μM) for 24 hours. After treating with CCK8 reagent (Donjindo, CK04) diluted 1 / 10 in DMEM medium for 3 hours, the absorbance was measured at 450 nm, and the results are shown in Figure 1.
[0049] [Experimental Example 2] Evaluation of Autophagy Activation
[0050] To confirm the autophagy-activating effect of cortexolone, human-derived fibroblasts were treated with cortexolone at different concentrations (10 μM, 25 μM) for 24 hours, after which the cells were lysed to prepare cell lysates. Cell lysates containing equal amounts of protein were separated by protein size using electrophoresis through protein quantification, and the relative protein expression levels were confirmed by western blotting using antibodies specific to MMP1 and LC3 II; the results are shown in Figure 2. The use of equal amounts of protein was verified as a loading control using an antibody specific to ACTB (beta-actin).
[0051] As can be seen in Figure 2, it was confirmed that the expression of LC3 II increased due to the activation of autophagy by treatment with cortexolone. In addition, it was confirmed that the expression of MMP1 decreased due to the activation of autophagy by treatment with cortexolone.
[0052] [Experimental Example 3] Evaluation of the Inhibitory Effect of MMP-1 Enzyme Expression
[0053] Human-derived fibroblasts were treated with 25 μM of cortexolone for 24 hours and then lysed to produce cell lysates. Through protein quantification, cell lysates containing equal amounts of protein were separated by protein size using electrophoresis, and the relative protein expression levels were confirmed by western blotting using antibodies specific to collagen 1 and MMP1. The use of equal amounts of protein was verified as a loading control using an antibody specific to ACTB (beta-actin), and the results are shown in Figure 3.
[0054] As can be seen in Figure 3, it was confirmed that the expression of MMP1, an enzyme that degrades collagen, decreased and the expression of collagen 1 increased upon treatment with cortexolone.
[0055] [Formulation Example 1] Liquid ampoule
[0056] A liquid ampoule was prepared by a conventional method according to the composition listed in Table 1 below.
[0057] ingredient Content (weight%) Cortexolon 1.2 Arginine 0.50 Green tea polyphenols 0.05 Indigestible maltodextrin 1.00 Vitamin C 0.10 Citric acid 0.10 spices 0.05 purified water Remaining amount total 100.00
[0058] [Formulation Example 2] Soap
[0059] Soap was prepared using a conventional method according to the composition listed in Table 2 below.
[0060] ingredient Content (weight%) Cortexolon 1.50 titanium dioxide 0.20 polyethylene glycol 0.80 glycerin 0.50 Ethylenediaminetetraacetic acid 0.05 sodium 1.00 pigment 0.20 Soap scent 0.20 Soap base Remaining amount total 100.00
[0061] [Formulation Example 3] Lotion
[0062] A lotion was prepared using a conventional method according to the composition listed in Table 3 below.
[0063] ingredient Content (weight%) Cortexolon 1.50 L-ascorbic acid-2-magnesium phosphate 1.00 collagen 1.00 Sodium citrate 0.10 citric acid 0.05 Licorice extract 0.20 1,3-Butylene Glycol 3.00 purified water Remaining amount total 100.00
[0064] [Formulation Example 4] Cream
[0065] A cream was prepared using a conventional method according to the composition listed in Table 4 below.
[0066] ingredient Content (weight%) Cortexolon 1.50 polyethylene glycol monostearate 2.00 Self-emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-actylhenic acid glyceryl 6.00 sphingoglycolipid 1.00 1,3-Butylene Glycol 7.00 purified water Remaining amount total 100.00
[0067] [Formulation Example 5] Pack
[0068] A pack was manufactured using a conventional method according to the composition listed in Table 5 below.
[0069] ingredient Content (weight%) Cortexolon 1.50 Polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate 1.00 Lauroylhydroxyproline 1.00 collagen 2.00 1,3-Butylene Glycol 3.00 ethanol 5.00 purified water Remaining amount total 100.00
[0070] [Formulation Example 6] Liquid formulation
[0071] A cosmetic liquid formulation was prepared by a conventional method according to the composition listed in Table 6 below.
[0072] ingredient Content (weight%) Cortexolon 1.50 hydroxyethylenecellulose 12.00 Xanthan sword 2.00 1,3-Butylene Glycol 6.00 glycerin 4.00 sodium hyaluronate 5.00 purified water Remaining amount total 100.00
[0073] [Formulation Example 7] Soft capsule
[0074] 200 mg of cortexolone, 160 mg of L-carnitine, 320 mg of soybean oil, 2 mg of palm oil, 8 mg of hydrogenated vegetable oil, 4 mg of yellow beeswax, and 6 mg of lecithin were mixed and filled into one capsule according to a conventional method to produce a soft capsule.
[0075] [Formulation Example 8] Tablet
[0076] 200 mg of cortexolone, 500 mg of galactooligosaccharide, 80 mg of lactose, and 220 mg of maltose were mixed and granulated using a fluid bed dryer, then 6 mg of sugar ester was added and the mixture was compressed using a tablet press to produce tablets.
[0077] [Formulation Example 9] Granules
[0078] 200 mg of cortexolone, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, formed into granules using a fluid bed granulator, and then filled into a bag to produce a granulated product.
[0079] [Formulation Example 10] Drink
[0080] 180 mg of cortexolone, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide were mixed, and 500 ml of purified water was added to fill each bottle with 200 ml. After filling the bottles, the mixture was sterilized at 130°C for 4 to 5 seconds to produce a drinkable beverage.
Claims
Claim 1 A composition for improving skin wrinkles comprising cortexolone, its salt, hydrate, or solvate as an active ingredient. Claim 2 A composition according to claim 1, wherein the cortexolone, its salt, hydrate, or solvate is administered at a dosage of 1.7 to 17 mg / kg / day. Claim 3 In claim 1, the composition is a composition that activates intracellular autophagy. Claim 4 In claim 1, the composition is a composition that inhibits the expression of MMP-1 enzyme. Claim 5 In any one of claims 1 to 4, the composition is a food composition. Claim 6 A composition according to any one of claims 1 to 4, wherein the composition is a cosmetic composition. Claim 7 A pharmaceutical composition for the prevention or treatment of atopic dermatitis, psoriasis, eczema, or erythema, comprising cortexolone, its salt, hydrate, or solvate as an active ingredient. Claim 8 A food composition for the prevention or improvement of atopic dermatitis, psoriasis, eczema, or erythema, comprising cortexolone, its salt, hydrate, or solvate as an active ingredient. Claim 9 A composition according to claim 7 or 8, wherein the composition activates autophagy, and the autophagy is autophagy in skin cells. Claim 10 A composition according to claim 7 or 8, wherein the composition activates autophagy, and the autophagy is autophagy in skin fibroblasts. Claim 11 A composition according to claim 7 or 8, wherein the cortexolone, its salt, hydrate, or solvate is administered at a dosage of 1.7 to 17 mg / kg / day. Claim 12 delete Claim 13 delete
Citation Information
Patent Citations
High concentration formulation
KR1020180019680A
Composition for skin Anti-wrinkle comprising maslinic derivatives
KR1020200065622A
